Methotrexate and mitomycin for patients with metastatic transitional cell carcinoma of the urinary tract.
Sixteen patients who had received no prior chemotherapy were treated with methotrexate and mitomycin for metastatic transitional cell carcinoma of the urinary tract. Five patients achieved partial response, with a median duration of 3 months (range, 3-8), but the trial has been abandoned because of severe toxic effects in six of the 16 patients. This combination appears to be more toxic and no more effective than methotrexate alone.
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage* / Q000009:adverse effects; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage* / Q000009:adverse effects; D009362:Neoplasm Metastasis; D014571:Urologic Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D008937:Mitomycins; D016685:Mitomycin; D008727:Methotrexate